Clinical trials: Retinal Neovascularization
Retinal Neovascularization
Daily Testing at Home by NV-AMD Subjects With Notal Home OCT.
The purpose of this study is to evaluate the ability of subjects with NV-AMD to perform sequential daily self-imaging of their eyes with the self-operated Notal Home OCT device in their homes for 90 days without on-site…
- Trial name
- NCT04650672
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Notal Vision Inc.
Retinal Neovascularization
Study of the Modification of the Retinal Nerve Fiber Layer in Patients Treated With Intravitreous Injection of Anti-VEGF
The intra-vitreous injection (IVT) of anti-VEGF (vascular endothelial growth factor) is currently the standard treatment for retinal neovascularization. The VEGF stimulates endothelial cells' proliferation and migration.
- Trial name
- IVT-RNFL (NCT02876198)
- Testing
- Gonioscopy
- Where
- 3 sites in France
- Volunteers
- 74 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
Time Efficiency Comparison of Two IntraVitreal Injection Techniques
Prospective, single-center, randomized, clinical trial (RCT) comparing the time efficiency and safety of a single-use intravitreal injection (IVI) guide versus a traditional technique using a dual blade speculum among patients…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion With Macular Edema, Uveitic Macular Edema
- Trial name
- TIVI (NCT04455399)
- Testing
- Intravitreal injection guide (Malosa), Dual Blade Eyelid Speculum
- Where
- Philippines
- Volunteers
- 200 people
- Sponsor
- Peregrine Eye and Laser Institute
Neovascular (Wet) Age-related Macular Degeneration
Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications
This study is designed as an observational, non-interventional, multicenter, open label, single arm study in patients being treated with Lucentis® for any approved indication included in the local product posology.
- Trial name
- PACIFIC (NCT04847895)
- Testing
- Lucentis
- Where
- 175 sites in Germany, Netherlands and 1 more
- Volunteers
- 5,500 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration, Wet Macular Degeneration
EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
Clinical and genetic evaluation of individuals treated with intravitreal aflibercept injection (Eylea) for neovascular age-related macular degeneration (wet AMD)
- Trial name
- EAGLE (NCT02689518)
- Testing
- Intravitreal aflibercept injection
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Diabetic Retinopathy, Retinal Neovascularisation
Ranibizumab in Diabetic Vitrectomy. A Prospective, Randomised Controlled Trial of Ranibizumab Pre-treatment in Diabetic Vitrectomy - a Pilot Study
This study will evaluate the effect of ranibizumab on patients undergoing vitrectomy surgery for the complications of diabetic retinopathy.
- Trial name
- RaDiVit (NCT01306981)
- Testing
- Ranibizumab, Saline
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Moorfields Eye Hospital NHS Foundation Trust
Choroidal Neovascularization Secondary to Pathologic Myopia
A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia.
The primary objective of the study was to investigate current criteria driving re-treatment in patients affected by Choroidal Neovascularization (CNV) secondary to Pathologic Myopia (PM) and experiencing a relapse of the disease…
- Trial name
- OLIMPIC (NCT02034006)
- Testing
- Ranibizumab
- Where
- 31 sites in Italy
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Conjunctivitis, Glaucoma
Feasibility Study and Preliminary Application Study on Iris OCTA
All participants will underwent imaging using the OCTA system (Zeiss) with the anterior segment optical adaptor lens. The main outcomes are iris blood flow density and vascular density.
- Conditions
- Conjunctivitis, Glaucoma, Myopia, Diabetic Retinopathy
- Trial name
- NCT03631108
- Testing
- OCTA (ZEISS)
- Volunteers
- 4,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Eye Disease Prevention and Treatment Center
Retinopathy of Prematurity
Safety and Efficacy of Propranolol 0.2% Eye Drops in Treating Retinopathy of Premature: A Pilot Study (DROP-ROP-0.2%)
The aim of the present study is to evaluate the safety and efficacy of propranolol 0.2% eye drops in treating preterm newborns with a precocious stage of retinopathy of prematurity (ROP).
- Trial name
- NCT02504944
- Testing
- Propranolol 0.2% eye drops
- Where
- 7 sites in Italy
- Volunteers
- 98 people
- Sponsor
- Meyer Children's Hospital IRCCS
Neovascularization, Macular Degeneration
Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection
Background/aims: Aflibercept is an approved therapy for neovascular macular degeneration (AMD), diabetic macular edema (DME), retinal vein occlusion and other retinal conditions.
- Conditions
- Neovascularization, Macular Degeneration, Diabetic Retinopathy, Retinal Vein Occlusion
- Trial name
- Zaltrap (NCT02486484)
- Testing
- ziv-aflibercept
- Where
- Lebanon
- Volunteers
- 100 people
- Sponsor
- Rafic Hariri University Hospital
Macular Degeneration, Age-Related Maculopathies
Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD)
This Phase 1 clinical research study will examine the safety and tolerability of an experimental gene transfer agent, AAV2-sFLT01, in patients with Neovascular Age-Related Macular Degeneration (AMD).
- Conditions
- Macular Degeneration, Age-Related Maculopathies, Age-Related Maculopathy, Maculopathies, Age-Related
- Trial name
- NCT01024998
- Testing
- AAV2-sFLT01
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Genzyme, a Sanofi Company
Eye Diseases, Macular Degeneration
Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of OPT-302 With or Without Lucentis™ in Patients With Wet AMD
The purpose of this first-in-human study is to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics of OPT-302 administered as monthly intravitreal injections for 3 months with and without Lucentis™ in patients with…
- Conditions
- Eye Diseases, Macular Degeneration, Retinal Diseases, Retinal Degeneration
- Trial name
- NCT02543229
- Testing
- OPT-302, Lucentis™
- Where
- 14 sites in United States
- Volunteers
- 51 people
- Sponsor
- Opthea Limited
Macular Degeneration, Age-related Maculopathies
Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration
The study will involve approximately 40 subjects aged 55 or above who have exudative age-related macular degeneration (wet AMD).
- Conditions
- Macular Degeneration, Age-related Maculopathies, Age-related Maculopathy, Maculopathies,Age-related
- Trial name
- AMD (NCT01494805)
- Testing
- rAAV.sFlt-1, Control (ranibizumab alone)
- Where
- Australia
- Volunteers
- 40 people
- Sponsor
- Lions Eye Institute, Perth, Western Australia
Diabetic Retinopathy, Macular Degeneration
Screening for Studies on Retinovascular Diseases
This screening protocol is designed to help recruit patients for National Eye Institute (NEI) studies of the retina, such as diabetic retinopathy and macular degeneration.
- Conditions
- Diabetic Retinopathy, Macular Degeneration, Pathologic Neovascularization, Retinal Disease
- Trial name
- NCT00001733
- Where
- United States
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Macular Degeneration, Retinal Vein Occlusion
Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders
This study will evaluate the safety and effectiveness of a new formulation of triamcinolone acetonide for the treatment of retinal blood vessel disorders.
- Trial name
- NCT00071227
- Testing
- Triamcinolone Acetonide (TAC-PF)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- National Eye Institute (NEI)
Macular Degeneration, Retinal Vein Occlusion
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
The use of intravitreal injections of corticosteroid (triamcinolone acetonide) appears to be a promising treatment for a variety of ocular diseases associated with inflammation.
- Conditions
- Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
- Trial name
- NCT00101764
- Testing
- Triamcinolone Acetonide
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Eye Institute (NEI)
Retinal Vein Occlusion
Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO
The study is intended to characterize the clinical benefit regarding safety and efficacy of a long term treatment with Lucentis in comparison with Ozurdex over an additional 6 months and a 3-month follow-up period, following the…
- Trial name
- NCT01580020
- Testing
- RFB002, Dexamethasone
- Where
- 37 sites in Germany
- Volunteers
- 175 people
- Sponsor
- Novartis Pharmaceuticals
Choroidal Neovascularization, Retinal Pigment Epithelial Detachment
Triple Treatment for Detachment of Retinal Pigment Epithelium Secondary to Polypoidal Choroidal Vasculopathy
Study the effectiveness of the treatment detachment of retinal pigment epithelium secondary to polypoidal choroidal vasculopathy. Efficacy will be assessed by regression of polyp area after twelve months, compared to baseline.
- Trial name
- NCT01666236
- Testing
- Triple Therapy
- Where
- Brazil
- Sponsor
- Federal University of São Paulo
Retinopathy of Prematurity
Safety and Efficacy of Propranolol Eye Drops in Treating Retinopathy of Premature
The aim of the present study is to evaluate the safety and efficacy of propranolol eye drops in preterm newborns with a precocious stage of retinopathy of prematurity (ROP).
- Trial name
- DROP-PROP (NCT02014454)
- Testing
- Propranolol eye drops
- Where
- 2 sites in Italy
- Volunteers
- 23 people
- Sponsor
- Meyer Children's Hospital IRCCS
Retinal Neovascularization
Squalamine for the Treatment in Proliferative Diabetic Retinopathy
The purpose of this study is to determine the efficacy in the use of topical Squalamine Lactate Ophthalmic Solution, 0.2% in the treatment of retinal neovascularization resulting from proliferative diabetic retinopathy.
- Trial name
- NCT01769183
- Testing
- Squalamine Lactate ophthalmic solution 0.2%
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Elman Retina Group